The Trump administration's Gold Card visa can now be yours, Commerce Secretary Howard Lutnick said, arguing that the new immigration program will bring renewed investment and ideas from top talent ...

Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...

With the year's end approaching, numerology encourages us to let go of specific behaviors linked to our birth numbers to welcome a more enriching future. 'Ones' might need to ease their grip on ...

It's been a long time since we've gotten a new email from beloved animated internet weirdo Strong Bad, but the drought is over. For the first time since 2022, the lucha-masked star of the Homestar ...

Apple unveiled the iPhone 17 lineup at its annual September event, including its first new phone model in years—the ultrathin iPhone Air. WSJ’s Nicole Nguyen reported from Apple headquarters in ...

The Trump administration’s crack-down on international students has led to a decrease of students on University of Colorado campuses but not as much as forecast at some schools. The Trump ...

Less than two months after it acquired rival AI coding platform Windsurf, the San Francisco.startup Cognition today announced it has raised more than $400 million at a $10.2 billion valuation and that ...

There is strong bipartisan support for the Energy Star program in Congress, though its status remains in doubt. Bills from the House and Senate Appropriations Committees call for continued funding of ...

The Oklahoma Partnership for School Readiness said 55% of Oklahomans currently live in a childcare desert, including many families in both Tulsa and Oklahoma City. The Oklahoma Strong Start program at ...

Impulse Space plans to provide GEO rideshare missions using its Helios tug. Credit: Impulse Space SALT LAKE CITY — A year after announcing plans to offer rideshare missions to geostationary orbit, ...

Pfizer's beleaguered obesity strategy has hit another setback as the pharma jettisoned its third and final GLP-1 agonist, citing poor data and tough competition. Pfizer's last remaining GLP-1 agonist, ...